TickerFacts.

Aclarion, Inc. (ACON): Revenue

Annual figures by period end, from SEC filings.

$75.7K
Year ended 2025-12-31
$83.8K
Trailing 12 months to 2026-06-30
+7.8%
3-year compound annual growth
2021-12-31: $60.3K2022-12-31: $60.4K2023-12-31: $75.4K2024-12-31: $45.7K2025-12-31: $75.7K$75.7K
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$75.7K+65.6%2026-03-18, From 2025-01-01
2024-12-31$45.7K-39.4%2026-03-18, From 2024-01-01
2023-12-31$75.4K+24.8%2025-04-09, From 2023-01-01
2022-12-31$60.4K+0.3%2024-03-28, From 2022-01-01
2021-12-31$60.3Kn/a2023-06-12, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Aclarion, Inc. (ACON)2025-12-31$75.7K+65.6%
Sera Prognostics, Inc. (SERA)2025-12-31$81.0K+5.2%
YD Bio Ltd (YDES)2025-12-31$596.8K+16.9%
BioNexus Gene Lab Corp (BGLC)2025-12-31$7.42M-21.9%
American Shared Hospital Services (AMS)2025-12-31$28.08M-0.9%
CapForce Inc. (CFOR)2025-12-31$30.20M+481.2%
Exagen Inc. (XGN)2025-12-31$66.58M+19.7%
Personalis, Inc. (PSNL)2025-12-31$69.65M-17.7%
Biodesix Inc (BDSX)2025-12-31$88.50M+24.1%

Compare ACON, SERA, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗